In fact, although present in other compartments of the organism, this enzyme is overexpressed in the CNS of patients with neurodegenerative diseases, so that a given GSK-3β inhibitor to treat such diseases must have more affinity to the CNS than to the blood (which will distribute the drug to other compartments). This evidence concerns the gene GSK3B and neurodegenerative disease.